Previous trials of adjuvant chemotherapy for oesophagogastric cancer 
Although the incidence of gastric cancer has declined steadily over the past 50 years (Coggon and Inskip, 1994) , it remains the second most common tumour worldwide and the fourth commonest in Europe. Surgery alone is the treatment of choice for tumours confined to the mucosa and submucosa, achieving cure rates of more than 80% (Thompson and Van Heerden, 1993) . When disease is locally advanced (T3/T4) curative surgery is possible in only a minority of patients (Rahamin and Cham, 1993; McCulloch, 1994) and disease recurrence after potentially curative resection in locally advanced gastric cancer occurs in approximately 80% of the patients within 5 years of surgery (Girling, 1992; Weese and Nussbaum, 1992) .
Gastric cancer is one of the more chemosensitive cancers of the GI tract, evidenced by the relatively high response rates to chemotherapy in patients with inoperable or metastatic disease (MacDonald et al., 1980; Wils et al., 1986; Lerner et al., 1992; Findlay et al., 1994) . In the adjuvant setting, however, the value of chemotherapy is less clear cut, with several randomised trials failing to show any significant benefit from adjuvant chemotherapy (Wils and Bleiberg, 1988; Allum et al., 1989; Coombes et al., 1990) . A recent meta-analysis of 11 randomised studies (Hermans et al., 1993) was initially reported supporting the conclusion that adjuvant chemotherapy offers no survival benefit. However, the amended results (Hermans and Bonencamp, 1994) , including two further trials, showed a small but statistically significant effect in favour of adjuvant therapy. Moreover, the regimens employed in these studies could be expected to produce responses in only 20-40% of patients with advanced disease (Cocconi, 1994) , while second-generation regimens, such as ECF and FAMTX (5-fluorouracil, doxorubicin, methotrexate), produce much higher response rates (Wils et al., 1986; Findlay et al., 1994) . Thus, adjuvant therapy with these combinations may significantly improve the outcome.
Oesophageal cancer is less common than gastric cancer but its incidence is rising (Coggon and Inskip, 1994) . The prognosis is similarly poor, with 5 year survival after curative resection less than 20% for stages II and III. The addition of radiotherapy to surgery has not resulted in any significant benefit in patients with advanced disease (Ellis and Cunningham, 1994) . However, chemotherapy and radiotherapy in locally advanced disease has proved more effective than radiotherapy alone (Sichy et al., 1990; Herscovic et al., 1992) , suggesting that chemotherapy may have a significant role.
The ECF regimen, developed by the GI Unit of the Royal Marsden Hospital, consists of epirubicin, cisplatin and continuous infuision of 5-FU. A phase II study of 139 patients with locally advanced and metastatic gastro-oesophageal cancer showed high response rates (70%), with approximately 13% of the patients achieving complete remission (Findlay et al., 1994) Before trial entry, patients were required to have a normal computerised tomographic (CT) scan of the thorax, abdomen and pelvis, a creatinine clarance of more than 40 ml min-l and a bilirubin of less than 30mmol 1'. All patients were treated between 6 and 10 weeks from surgery and gave their written consent to participate in the study, which was approved by the Royal Marsden Research Ethics Committee.
Intravenous access
Chemotherapy was given through a double-lumen indwelling catheter (Quintin, USA) placed in the subclavian vein via a subcutaneous tunnel under local anastesia (Stacey et al., 1990) . Warfarin (1 mg daily) was adninisered throughout the treatment to prevent line thrombosis. Lines were removed under local anaesthetic after the termination of treatment.
Chemotherapy
The first patient received eight cycles of ECF. Subsequently, it was planned that each patient would receive six cycles of chemotherapy. 5-FU was i as a continuous intravenous infusion at a dose of 200mg min2 using a portable battery-powered pump (Infumed no. 350, Medex, USA, or Graseby no. M26, Graseby, UK). All patients received prophylactic nystatin and sucralphate suspensions to prevent mouth ulceration. Patients developing diarrhoea or mucositis had a treatment break until these symptoms resolved and would restart at a 50 mg m 2 dose reduction. A dose reduction of 100mgm-2 was used for patients with toxicity of grade 3 or 4. Patients developing palmar-plantar syndrome were given pyridoxine 50 mg t.d.s. and if this toxicity did not improve, 5-FU was discontinued for 1 week and restarted at a dose of 150mgm-2.
Cisplatin was inisd at 60 mgm2 every 3 weeks with stamndard hydration (Findlay et al., 1994) . Dose (Rubin and Wasserman, 1988) . Alopecia was observed in the majority of the patients (82%). The other non-haematological side-effects were: nausea and/or vomiting (44%), diarrhoea (45.5%), stomatitis (34%), infection (24%), palmar plantar erytma (20%) and neuropathy (7%). These side-effects were mild in most cases. Grade 3 or 4 nonhaematological toxicity was observed in only five cases out of 51 recorded toxicities (10%). Transient loss of taste was reported by ten patients (34.5%). Haematological toxicity was mild with only five out of the 21 (24%) grade 3 or 4. Leucopenia was observed in 17 cases (58.5%) and thrombocytopenia in four cases (14%). Infections of indwelling catheters occurred in six cases (21%) leading in two patients to catheter roval and in one patient the catheter had to be removed due to venous thrombosis. In all three cases the catheter were successfully re-nserted.
Seven cycles (4.8%) were delayed due to toxicity, which was haematological in four, mucositis in one, nausea and vomiting in one and infection without leucopenia in the other. Only two patients required admission for complications associated with chemotherapy: one patient with postoperative intra-abdominal abscesses before chemotherapy Eight patients (27.5%) died during follow-up, six because of progressive disease. One patient had an unknown cause of death and the other patient had post-operative intraabdominal sepsis, tolerated only two courses of chemotherapy and died of septic complications 6 months after diagnosis with no evidence of recurrence on CT scan or liver biopsy. Figure 1 shows the overall survival and at the time of analysis the median survival had not been reached. One year, 2 year and 3 year survivals are shown in (Wils et al., 1991) . A meta-analysis of 13 randomised trials using such regimens has, however, shown a significant benefit in favour of chemotherapy, but the effect is small (Hermans and Bonencamp, 1994) . More recently developed combinations have superior response rates in advanced disease and are under investigation in the adjuvant setting.
Our phase II trial of ECF has shown similar results to these second-generation regimens but with less toxicity, particularly myelotoxicity (Findlay et al., 1994) . The main feature of ECF is the use of continuous infusion of 5-FU, which results in a considerable increase in the dose intensity of this drug compared with FAM (5-fluorouracil, doxorubicin, mitomycin C) and FAMTX. Continuous infusion of 5-FU has also proved to be less toxic than bolus administration in advanced colorectal carcinoma. (Lokich et al., 1989) with diarrhoea and stomatitis the dose-limiting toxicity. This relative lack of toxicity with high dose intensity makes infusional 5-FU an attractive component of an adjuvant combination regimen.
Toxicity with ECF was mild. Treatment was prematurely discontinued in only four cases, one of which was a consequence of delayed post-operative complications. Admission to hospital was necessary in only two cases. Although bone marrow toxicity was common, it was usually mild and it was not life-threatening. Additionally, the use of indwelling catheters was associated with minimal toxicity and good compliance. These results compare favourably with those reported with FAMTX and EAP (Kelsen et al., 1992; Lerner et al., 1992) . Bone marrow toxicity represents a serious complication of these regimens, particularly since patients receiving them have often undergone major thoracic or abdominal surgery, not infrequently associated with post-operative complications. The effect of ECF treatment on survival cannot be accurately evaluated from this pilot study, but the 3 year survival suggests that there may be a survival benefit, especially in stage III disease.
In conclusion, ECF is feasible to administer in the adjuvant setting to patients with oesophagogastric adenocarn v A cinomas. The results in stage III disease are particularly encouraging and support the investigation of this regimen in a prospective randomised trial comparing surgery plus chemotherapy with surgery alone. Such a study has just been launched by the Medical Research Council (MAGIC trial) and includes pre-and post-operative courses of ECF in the chemotherapy arm.
